U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C25H37NO4.C11H8O3
Molecular Weight 603.745
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALMETEROL XINAFOATE

SMILES

OC(=O)C1=CC=C2C=CC=CC2=C1O.OCC3=C(O)C=CC(=C3)C(O)CNCCCCCCOCCCCC4=CC=CC=C4

InChI

InChIKey=XTZNCVSCVHTPAI-UHFFFAOYSA-N
InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)

HIDE SMILES / InChI

Molecular Formula C11H8O3
Molecular Weight 188.1794
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C25H37NO4
Molecular Weight 415.5656
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/salmeterol-inhalation.html http://www.rxlist.com/serevent-diskus-drug.htm http://www.wikidoc.org/index.php/Salmeterol

Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these is not yet established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. It is FDA approved for the treatment of asthma, prevention of exercise-induced bronchospasm, maintenance treatment of chronic obstructive pulmonary disease. Common adverse reactions include musculoskeletal pain, headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, throat irritation, viral respiratory infection. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents. Coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

1994
Palliative
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

1994
Preventing
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

1994
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
319 pg/mL
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
167 pg/mL
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
464 pg × h/mL
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.72 h
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.5 h
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (5 patients)
Dizziness (2 patients)
Tremor (5 patients)
Palpitations (1 patient)
Muscle cramps (1 patient)
Sources:
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
Health Status: healthy
Age Group: 34.3
Sex: M
Sources:
Other AEs: Headache, Tremor...
Other AEs:
Headache (5 patients)
Tremor (5 patients)
Palpitations (3 patients)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Other AEs: Ear disorder, Pharyngitis...
Other AEs:
Ear disorder (4%)
Pharyngitis (6%)
Headache (17%)
Asthma (4%)
Skin rash (4%)
Urticaria (3%)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Other AEs: Nasal sinus congestion, Rhinitis...
Other AEs:
Nasal sinus congestion (9%)
Rhinitis (5%)
Headache (13%)
Asthma (3%)
Tracheobronchitis (7%)
Influenza (5%)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Other AEs: Hypertension, Throat irritation...
Other AEs:
Hypertension (4%)
Throat irritation (7%)
Congestion nasal (4%)
Sinusitis (4%)
Ear disorder (3%)
Nausea and vomiting (3%)
Cough (5%)
Rhinitis (4%)
Respiratory tract infection viral (5%)
Musculoskeletal pain (12%)
Muscle cramps (3%)
Headache (14%)
Dizziness (4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Muscle cramps 1 patient
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Palpitations 1 patient
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Dizziness 2 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Headache 5 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Tremor 5 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
Health Status: unhealthy
Age Group: 30
Sex: M+F
Sources:
Palpitations 3 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
Health Status: healthy
Age Group: 34.3
Sex: M
Sources:
Headache 5 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
Health Status: healthy
Age Group: 34.3
Sex: M
Sources:
Tremor 5 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
Health Status: healthy
Age Group: 34.3
Sex: M
Sources:
Headache 17%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Urticaria 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Asthma 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Ear disorder 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Skin rash 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Pharyngitis 6%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
Headache 13%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Asthma 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Influenza 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Rhinitis 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Tracheobronchitis 7%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Nasal sinus congestion 9%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
Musculoskeletal pain 12%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Headache 14%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Ear disorder 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Muscle cramps 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Nausea and vomiting 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Congestion nasal 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Dizziness 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Hypertension 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Rhinitis 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Sinusitis 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Cough 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Respiratory tract infection viral 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Throat irritation 7%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
unlikely
yes
yes
yes
yes (co-administration study)
Comment: Coadministration of inhaled Salmetrol and oral ketoconazole (strong CYP3A4 inhibitor) for 7 days increased Salmetrol AUC by 16-fold and Cmax by 1.4-fold. Coadministration of Erythromycin (moderate CYP3A4 inhibitor) increased inhaled Salmeterol Cmax,ss by 40% (3.6-beat/min in heart rate, 5.8-msec increase in QTc interval).
Page: 13-14, 21-22
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Salmeterol-induced vertigo.
1994 Nov
[Salmeterol-induced enuresis in children].
1996 May 22
Salmeterol inhibits the allergen-induced mononuclear cell proliferation and downregulates GM-CSF release and HLA-DR expression by monocytes.
1997
A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
1997 Dec 4
ACE inhibitors: a possible cause of unexplained anemia.
1998 Jan
Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients.
1998 May-Jun
Potential masking effects of salmeterol on airway inflammation in asthma.
1998 Sep
Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
1999
Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
1999 Aug
Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.
1999 Oct
Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells.
1999 Oct
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000 Aug
Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma.
2000 Sep
Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol.
2001 Jan-Feb
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
2004 Jan
Heat-induced degradation of overexpressed glucocorticoid receptor Separate protective roles of hsp90 and hsp70.
2005 Feb
Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
2005 Feb
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.
2005 Sep 15
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.
2006 Jun 20
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.
2007
Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard.
2007 Aug
Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity.
2007 Feb
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea.
2010 Apr
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
2010 Jul
The preclinical toxicology of salmeterol hydroxynaphthoate.
2010 May
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
2012 Jul 1
[Cushing's syndrome during HIV treatment: pharmacological interaction during use of ritonavir].
2013
Patents

Sample Use Guides

Asthma and Chronic Obstructive Pulmonary Disease: the usual dosage for adults and children 4 years of age and older is 1 inhalation (50 mcg) twice daily (morning and evening, approximately 12 hours apart). Exercise-Induced Bronchospasm: One inhalation of SEREVENT DISKUS at least 30 minutes before exercise.
Route of Administration: Respiratory
Since fibroblasts express beta2-adrenoreceptors, the effects of different concentrations (0.1-100 nM) of salmeterol on lung fibroblast proliferation and adhesion molecule expression were evaluated. A significant downregulation of ICAM-1 or H-CAM expression was demonstrated in the presence of Salmeterol, at all concentrations tested (0.1-100 nM; p<0.01).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:25:49 GMT 2025
Edited
by admin
on Mon Mar 31 18:25:49 GMT 2025
Record UNII
6EW8Q962A5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADVAIR HFA COMPONENT SALMETEROL XINAFOATE
Preferred Name English
SALMETEROL XINAFOATE
EP   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
SALMETEROL XINAFOATE [EP MONOGRAPH]
Common Name English
GR-33343 G
Code English
SALMETEROL XINAFOATE [USP-RS]
Common Name English
GR 33343 G
Code English
SALMETEROL 1-HYDROXY-2-NAPHTHOATE [MI]
Common Name English
SALMETEROL XINAFOATE [JAN]
Common Name English
SALMETEROL XINAFOATE [USP MONOGRAPH]
Common Name English
SALMETEROL XINAFOATE [EP IMPURITY]
Common Name English
SEREVENT
Brand Name English
SALMETEROL XINAFOATE [MART.]
Common Name English
ADVAIR COMPONENT SALMETEROL XINAFOATE
Brand Name English
SALMETEROL XINAFOATE [USAN]
Common Name English
AIRDUO RESPICLICK COMPONENT SALMETEROL XINAFOATE
Brand Name English
(±)-4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-M-XYLENE-.ALPHA.,.ALPHA.'-DIOL 1-HYDROXY-2-NAPHTHOATE
Common Name English
SALMETEROL XINAFOATE [ORANGE BOOK]
Common Name English
LIPO-102 COMPONENT SALMETEROL XINAFOATE
Common Name English
GR-33343X
Code English
SALMETEROL 1-HYDROXY-2-NAPHTHOATE
MI  
Common Name English
1,3-BENZENEDIMETHANOL, 4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-, (±)-, 1-HYDROXY-2-NAPHTHALENECARBOXYLATE
Common Name English
SALMETEROL XINAFOATE [VANDF]
Common Name English
Salmeterol xinafoate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
FDA ORPHAN DRUG 273208
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
Code System Code Type Description
EVMPD
SUB04314MIG
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
MERCK INDEX
m9745
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY Merck Index
USAN
BB-30
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
FDA UNII
6EW8Q962A5
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
DRUG BANK
DBSALT001372
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
NCI_THESAURUS
C61935
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
PUBCHEM
56801
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
CAS
94749-08-3
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
RXCUI
72616
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY RxNorm
RS_ITEM_NUM
1609603
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
EPA CompTox
DTXSID1045798
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
SMS_ID
100000091381
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
ChEMBL
CHEMBL1263
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
DAILYMED
6EW8Q962A5
Created by admin on Mon Mar 31 18:25:49 GMT 2025 , Edited by admin on Mon Mar 31 18:25:49 GMT 2025
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY